Bank of America
TVRD

Bank of America’s Tvardi Therapeutics TVRD Stock Holding History

Bank of America’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-278
Closed -$215K – 7563
2019
Q2 		$215K Sell
278
-7,644
-96% -$5.37M ﹤0.01% 5580
2019
Q1 		$5.59M Buy
+7,922
New +$4.74M ﹤0.01% 3053
2017
Q3 		– Sell
-36
Closed -$20K – 7328
2017
Q2 		$20K Buy
+36
New +$22.8K ﹤0.01% 6231

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Bank of America's TVRD Position: Q1 2026 in Review

Bank of America sold out of Tvardi Therapeutics (TVRD) in Q1 2026, closing a stake of 25,382 shares — an estimated $109K sold.

Bank of America first reported a position in TVRD in Q2 2014 and held it in 47 quarters. The position peaked at $17.2M in Q2 2020. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.

  • Bank of America reported no remaining Tvardi Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 25,382 Tvardi Therapeutics shares in Q1 2026, an estimated $109K.
  • Bank of America first reported a position in Tvardi Therapeutics in Q2 2014 and held it in 47 quarters.
  • Bank of America's Tvardi Therapeutics position peaked at $17.2M in Q2 2020.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.